Gastro Medicine UK Ltd SC434463 false 2024-05-01 2025-04-30 2025-04-30 The principal activity of the company is Medical Consultancy Digita Accounts Production Advanced 6.30.9574.0 true SC434463 2024-05-01 2025-04-30 SC434463 2025-04-30 SC434463 core:CurrentFinancialInstruments 2025-04-30 SC434463 core:CurrentFinancialInstruments core:WithinOneYear 2025-04-30 SC434463 bus:SmallEntities 2024-05-01 2025-04-30 SC434463 bus:AuditExemptWithAccountantsReport 2024-05-01 2025-04-30 SC434463 bus:FilletedAccounts 2024-05-01 2025-04-30 SC434463 bus:SmallCompaniesRegimeForAccounts 2024-05-01 2025-04-30 SC434463 bus:RegisteredOffice 2024-05-01 2025-04-30 SC434463 bus:Director1 2024-05-01 2025-04-30 SC434463 bus:PrivateLimitedCompanyLtd 2024-05-01 2025-04-30 SC434463 bus:Agent1 2024-05-01 2025-04-30 SC434463 core:KeyManagementPersonnel 2024-05-01 2025-04-30 SC434463 countries:Scotland 2024-05-01 2025-04-30 SC434463 2023-05-01 2024-04-30 SC434463 2024-04-30 SC434463 core:CurrentFinancialInstruments 2024-04-30 SC434463 core:CurrentFinancialInstruments core:WithinOneYear 2024-04-30 iso4217:GBP xbrli:pure xbrli:shares

Registration number: SC434463

Gastro Medicine UK Ltd
Unaudited Filleted Financial Statements
for the Year Ended 30 April 2025

Gastro Medicine UK Ltd

Contents

Company Information | 1
Balance Sheet | 2
Notes to the Unaudited Financial Statements | 3 to 5

Gastro Medicine UK Ltd

Company Information

Director | D Watts

Registered office | Unit 26, Dunfermline Business Centre Izatt Avenue Dunfermline Fife KY11 3BZ

Accountants | M&S Accountancy and Taxation Limited Unit 26, Dunfermline Business Centre Izatt Avenue Dunfermline Fife KY11 3BZ

Gastro Medicine UK Ltd

(Registration number: SC434463)
Balance Sheet as at 30 April 2025

| Note | 2025 £ | 2024 £
Current assets |  |  |
Debtors | 4 | 590,208 | 391,049
Cash at bank and in hand |  | 136,472 | 155,067
|  | 726,680 | 546,116
Creditors: Amounts falling due within one year | 5 | (132,817) | (49,942)
Net assets |  | 593,863 | 496,174
Capital and reserves |  |  |
Called up share capital | 6 | 100 | 100
Retained earnings |  | 593,763 | 496,074
Shareholders' funds |  | 593,863 | 496,174

For the financial year ending 30 April 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

• | The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and
• | The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the director has not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the director on 23 April 2026

......................................... D Watts Director

Gastro Medicine UK Ltd

Notes to the Unaudited Financial Statements for the Year Ended 30 April 2025

1 | General information

The company is a private company limited by share capital, incorporated in Scotland.

The address of its registered office is:
Unit 26, Dunfermline Business Centre
Izatt Avenue
Dunfermline
Fife
KY11 3BZ

These financial statements were authorised for issue by the director on 23 April 2026.

2 | Accounting policies

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Revenue recognition

Turnover comprises the invoiced value of goods and services supplied by the company, net of VAT and trade discounts. Turnover is recognised on the accruals basis.

Tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.
Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.
Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Gastro Medicine UK Ltd

Notes to the Unaudited Financial Statements for the Year Ended 30 April 2025

Provisions

Provisions are recognised when the company has a present obligation as a result of a past event which it is more probable than not will result in an outflow of economic benefits that can be reasonably estimated.

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

Financial instruments

Classification
The company has elected to apply the provisions of Section 11 Basic Financial Instruments and Section 12 Other Financial Instruments Issues of FRS 102 to all of its financial instruments.
Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.
Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

3 | Staff numbers

The average number of persons employed by the company (including the director) during the year, was 1 (2024 - 1).

4 | Debtors

Current | 2025 £ | 2024 £
Trade debtors | 19,772 | 12,085
Other debtors | 570,436 | 378,964
| 590,208 | 391,049

Gastro Medicine UK Ltd

Notes to the Unaudited Financial Statements for the Year Ended 30 April 2025

5 | Creditors

Creditors: amounts falling due within one year

| 2025 £ | 2024 £
Taxation and social security | 63,249 | 30,148
Accruals and deferred income | 5,333 | 2,501
Other creditors | 64,235 | 17,293
| 132,817 | 49,942

6 | Share capital

Allotted, called up and fully paid shares

| 2025 | 2024
| No. | £ | No. | £
A Ordinary of £1 each | 60 | 60 | 60 | 60
B Ordinary of £1 each | 15 | 15 | 15 | 15
C Ordinary of £1 each | 5 | 5 | 5 | 5
D Ordinary of £1 each | 5 | 5 | 5 | 5
E Ordinary of £1 each | 5 | 5 | 5 | 5
F Ordinary of £1 each | 10 | 10 | 10 | 10
| 100 | 100 | 100 | 100

7 | Related party transactions

Key management personnel

At the balance sheet date, David Watts was due the company £422,240 (2024 - £278,710).
Interest was charged on the loan at a rate of 2.25% until 5 April 2025, after which the rate increased to 3.75%. Advances totalling £135,142 and payments totalling £500 were made during the year. The loan is unsecured and repayable on demand.